Combining in vitro diagnostics with in vivo imaging for earlier detection of pancreatic ductal adenocarcinoma: Challenges and solutions1

Radiology

Volumn 277, Issue 3, 2015, Pages 644-661

  Laeseke, Paul F ^a   Chen, Ru ^b   Jeffrey, R Brooke ^a   Brentnall, Teresa A ^b   Willmann, Jürgen K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; CA 125 ANTIGEN; CA 19-9 ANTIGEN; FBA PEG28 A20FMDV2 F 18; FLUORODEOXYGLUCOSE F 18; GELSOLIN; GLUCOSE TRANSPORTER 1; INTERCELLULAR ADHESION MOLECULE 1; LUMICAN; MICRORNA; MICRORNA 155; MICRORNA 196A; MICRORNA 21; MICRORNA 210; PHENYLALANYLGLUTAMYLASPARTYLLEUCINE F 18; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C RECEPTOR; STRATIFIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CONTRAST MEDIUM; PLASMA PROTEIN;

ABDOMINAL PAIN; APPARENT DIFFUSION COEFFICIENT; AREA UNDER THE CURVE; B SCAN; BIOENGINEERING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CHRONIC PANCREATITIS; CLINICAL TRIAL (TOPIC); CODON; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION COEFFICIENT; DNA METHYLATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FINE NEEDLE ASPIRATION BIOPSY; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; JAUNDICE; KRAS2 GENE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MICRO-COMPUTED TOMOGRAPHY; MICROBUBBLE; MICROCIRCULATION; MORBIDITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; UNITED STATES; ADENOCARCINOMA; BLOOD; CARCINOMA, PANCREATIC DUCTAL; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; BIOMARKERS; BLOOD PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CONTRAST MEDIA; COST-BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DNA METHYLATION; EARLY DETECTION OF CANCER; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICRORNAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84948800078     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015141020     Document Type: Review

References (145)

1. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. Washington, DC: American Registry of Pathology, 2007.
2. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007;194(4,Suppl):S84-S86.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
4. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91(5):586-594.
5. Lowenfels AB, Sullivan T, Fiorianti J, Maisonneuve P. The epidemiology and impact of pancreatic diseases in the United States. Curr Gastroenterol Rep 2005;7(2):90-95.
6. Wang YY, Cui QC. Recent advances in gene change of pancreatic cancer [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26(1):79-82.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-1806.
8. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011;17(2):302-309.
9. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88(10):2239-2245.
10. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23(2):251-275.
11. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133(3):365-374.
12. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg 2010;44:293-311.
13. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64(7):2634-2638.
14. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134(1):95-101.
15. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10(1):88-95.
16. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14(11):1095-1103.
17. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10(9):1199-1210; discussion 1210-1211.
18. Zhang JF, Hua R, Sun YW, et al. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Asian Pac J Cancer Prev 2013;14(9):5133-5139.
19. Chatterjee D, Katz MH, Rashid A, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 2012;36(3):409-417.
20. Hermanek P. Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 1998;383(2):116-120.
21. Liu H, Li X, Xu Q, Lv S, Li J, Ma Q. Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer. Biochim Biophys Acta 2012;1826(1):112-120.
22. Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma: a collective study. Cancer 1996;78(5):986-990.
23. Gemmel C, Eickhoff A, Helmstädter L, Riemann JF. Pancreatic cancer screening: state of the art. Expert Rev Gastroenterol Hepatol 2009;3(1):89-96.
24. Helmstaedter L, Riemann JF. Pancreatic cancer: EUS and early diagnosis. Langenbecks Arch Surg 2008;393(6):923-927.
25. Pandharipande PV, Heberle C, Dowling EC, et al. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology 2015;275(1):177-187.
26. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131(4):247-255.
27. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003;57(1):23-29.
28. Brentnall TA. Pancreatic cancer surveillance: learning as we go. Am J Gastroenterol 2011;106(5):955-956.
29. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56(10):1460-1469.
30. Templeton AW, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. Surg Clin North Am 2013;93(3): 629-645.
31. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 2013;107(1):15-22.
32. Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011;17(4): 805-816.
33. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19(2): 182-186.
34. Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007; 95(2):142-147.
35. Olsen TS. The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. Acta Pathol Microbiol Scand [A] 1978;86A(5):361-365.
36. Shimizu M, Hayashi T, Saitoh Y, Itoh H. Interstitial fibrosis in the pancreas. Am J Clin Pathol 1989;91(5):531-534.
37. Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum Pathol 1984;15(7):677-683.
38. Pan S, Chen R, Brand RE, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res 2012;11(3):1937-1948.
39. Pan S, Chen R, Crispin DA, et al. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 2011;10(5):2359-2376.
40. Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013;108(2):361-369.
41. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009;2(9):807-813.
42. Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138(3):949-57. e1-e7.
43. Park JK, Ryu JK, Yoon WJ, et al. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 2012;41(1):95-101.
44. Liggett T, Melnikov A, Yi QL, et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010;116(7):1674-1680.
45. Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012;61(4):582-588.
46. Kersting S, Konopke R, Kersting F, et al. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology 2009;137(6):1903-1911.
47. Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001;38(2):105-112.
48. Hua YP, Liang LJ, Peng BG, Li SQ, Huang JF. Pancreatic head carcinoma: clinical analysis of 189 cases. Hepatobiliary Pancreat Dis Int 2009;8(1):79-84.
49. Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur Radiol 2002;12(1):151-165.
50. Okamoto Y, Kawamoto H, Takaki A, et al. Contrast-enhanced ultrasonography depicts small tumor vessels for the evaluation of pancreatic tumors. Eur J Radiol 2007;61(1):163-169.
51. Takeda K, Goto H, Hirooka Y, et al. Contrast-enhanced transabdominal ultrasonography in the diagnosis of pancreatic mass lesions. Acta Radiol 2003;44(1):103-106.
52. Dietrich CF, Braden B, Hocke M, Ott M, Ignee A. Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. J Cancer Res Clin Oncol 2008;134(6):635-643.
53. Shapiro RS, Wagreich J, Parsons RB, Stancato-Pasik A, Yeh HC, Lao R. Tissue harmonic imaging sonography: evaluation of image quality compared with conventional sonography. AJR Am J Roentgenol 1998;171(5):1203-1206.
54. Sofuni A, Iijima H, Moriyasu F, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005;40(5):518-525.
55. D'Onofrio M, Malagò R, Zamboni G, et al. Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. Pancreatology 2005;5(4-5):398-402.
56. D'Onofrio M, Zamboni G, Tognolini A, et al. Mass-forming pancreatitis: value of contrast-enhanced ultrasonography. World J Gastroenterol 2006;12(26):4181-4184.
57. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2(7):606-621.
58. Lee MX, Saif MW Screening for early pancreatic ductal adenocarcinoma: An urgent call! JOP 2009;10(2):104-108
59. Ahmad NA, Kochman ML, Brensinger C, et al. Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. Gastrointest Endosc 2003;58(1): 59-64.
60. Topazian M, Enders F, Kimmey M, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007;66(1):62-67.
61. Pysz MA, Willmann JK. Targeted contrastenhanced ultrasound: an emerging technology in abdominal and pelvic imaging. Gastroenterology 2011;140(3):785-790.
62. Wilson KE, Wang TY, Willmann JK. Acoustic and photoacoustic molecular imaging of cancer. J Nucl Med 2013;54(11):1851-1854.
63. Pysz MA, Machtaler SB, Seeley ES, et al. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. Radiology 2015; 274(3):790-799.
64. Bachawal SV, Jensen KC, Lutz AM, et al. Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model. Cancer Res 2013;73(6): 1689-1698.
65. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008;27(6): 855-866.
66. Rychak JJ, Graba J, Cheung AMY, et al. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 2007;6(5):289-296.
67. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256(2):519-527.
68. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007;13(1):323-330.
69. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010;45(2): 89-95.
70. Tardy I, Pochon S, Theraulaz M, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol 2010;45(10):573-578.
71. Foygel K, Wang H, Machtaler S, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology 2013;145(4):885-894. e3.
72. Kaneko OF, Willmann JK. Ultrasound for molecular imaging and therapy in cancer. Quant Imaging Med Surg 2012;2(2):87-97.
73. Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257(1):87-96.
74. Ahn SS, Kim MJ, Choi JY, Hong HS, Chung YE, Lim JS. Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol 2009;19(10):2448-2455.
75. Peddu P, Quaglia A, Kane PA, Karani JB. Role of imaging in the management of pancreatic mass. Crit Rev Oncol Hematol 2009;70(1):12-23.
76. Lu DS, Vedantham S, Krasny RM, Kadell B, Berger WL, Reber HA. Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Radiology 1996;199(3): 697-701.
77. Valls C, Andía E, Sanchez A, et al. Dualphase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002;178(4): 821-826.
78. Kaneko OF, Lee DM, Wong J, et al. Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma. J Comput Assist Tomogr 2010;34(5): 732-738.
79. Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology 2014;272(2): 322-344.
80. Klauss M, Stiller W, Fritz F, et al. Computed tomography perfusion analysis of pancreatic carcinoma. J Comput Assist Tomogr 2012;36(2):237-242.
81. Delrue L, Blanckaert P, Mertens D, Cesmeli E, Ceelen WP, Duyck P. Assessment of tumor vascularization in pancreatic adenocarcinoma using 128-slice perfusion computed tomography imaging. J Comput Assist Tomogr 2011;35(4): 434-438.
82. Lu N, Feng XY, Hao SJ, et al. 64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis. Acad Radiol 2011;18(1):81-88.
83. Kandel S, Kloeters C, Meyer H, Hein P, Hilbig A, Rogalla P. Whole-organ perfusion of the pancreas using dynamic volume CT in patients with primary pancreas carcinoma: acquisition technique, postprocessing and initial results. Eur Radiol 2009;19(11):2641-2646.
84. Xu J, Liang Z, Hao S, et al. Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging 2009;34(6):759-766.
85. Patel BN, Thomas JV, Lockhart ME, Berland LL, Morgan DE. Single-source dualenergy spectral multidetector CT of pan-creatic adenocarcinoma: optimization of energy level viewing significantly increases lesion contrast. Clin Radiol 2013;68(2): 148-154.
86. Montet X, Pastor CM, Vallée JP, et al. Improved visualization of vessels and hepatic tumors by micro-computed tomography (CT) using iodinated liposomes. Invest Radiol 2007;42(9):652-658.
87. Mukundan S Jr, Ghaghada KB, Badea CT, et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol 2006;186(2):300-307.
88. Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. II. Applications. Radiology 2012;264(2):349-368.
89. Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. I. Principles. Radiology 2012;263(3):633-643.
90. Danila D, Partha R, Elrod DB, Lackey M, Casscells SW, Conyers JL. Antibodylabeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography. Tex Heart Inst J 2009;36(5):393-403.
91. Wyss C, Schaefer SC, Juillerat-Jeanneret L, et al. Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol 2009;19(10):2487-2494.
92. Martens CL, Cwirla SE, Lee RY, et al. Peptides which bind to E-selectin and block neutrophil adhesion. J Biol Chem 1995;270(36): 21129-21136.
93. Bischoff J, Brasel C, Kräling B, Vranovska K. E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 1997;4(2):279-287.
94. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7(7):591-607.
95. Gilinsky NH, Bornman PC, Girdwood AH, Marks IN. Diagnostic yield of endoscopic retrograde cholangiopancreatography in carcinoma of the pancreas. Br J Surg 1986;73(7):539-543.
96. Menges M, Lerch MM, Zeitz M. The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc 2000;52(1):74-77.
97. Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging 2009;20(1):3-9.
98. Kim JK, Altun E, Elias J Jr, Pamuklar E, Rivero H, Semelka RC. Focal pancreatic mass: distinction of pancreatic cancer from chronic pancreatitis using gadoliniumenhanced 3D-gradient-echo MRI. J Magn Reson Imaging 2007;26(2):313-322.
99. Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C. State-of-theart magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging 2007;18(6):421-429.
100. Kelekis NL, Semelka RC. MRI of pancreatic tumors. Eur Radiol 1997;7(6):875-886.
101. Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250(6):957-963.
102. Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005;29(4): 438-445.
103. Hekimoglu K, Ustundag Y, Dusak A, et al. MRCP vs ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis 2008;9(3):162-169.
104. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356(9225):190-193.
105. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360(9329):307-308.
106. Ichikawa T, Erturk SM, Motosugi U, et al. High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am J Roentgenol 2007; 188(2):409-414.
107. Matsuki M, Inada Y, Nakai G, et al. Diffusion-weighed MR imaging of pancreatic carcinoma. Abdom Imaging 2007;32(4):481-483.
108. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivityencoding versus SPIO-enhanced MR imaging. Radiology 2006;239(1):122-130.
109. Muraoka N, Uematsu H, Kimura H, et al. Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations. J Magn Reson Imaging 2008;27(6):1302-1308.
110. Lemke A, Laun FB, Klauss M, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol 2009;44(12):769-775.
111. Takeuchi M, Matsuzaki K, Kubo H, Nishitani H. High-b-value diffusion-weighted magnetic resonance imaging of pancreatic cancer and mass-forming chronic pancreatitis: preliminary results. Acta Radiol 2008;49(4):383-386.
112. Fattahi R, Balci NC, Perman WH, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 2009;29(2):350-356.
113. Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol 2009;19(8):1981-1990.
114. Henriksen O. MR spectroscopy in clinical research. Acta Radiol 1994;35(2):96-116.
115. Cho SG, Lee DH, Lee KY, et al. Differentiation of chronic focal pancreatitis from pancreatic carcinoma by in vivo proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2005;29(2):163-169.
116. Ma X, Zhao X, Ouyang H, et al. The metabolic features of normal pancreas and pancreatic adenocarcinoma: preliminary result of in vivo proton magnetic resonance spectroscopy at 3. 0 T. J Comput Assist Tomogr 2011;35(5):539-543.
117. Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, O'Kennedy R. Molecular and magnetic resonance imaging: the value of immunoliposomes. Adv Drug Deliv Rev 2009;61(15):1402-1411.
118. Briley-Saebo KC, Mulder WJ, Mani V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging 2007;26(3):460-479.
119. Tan M, Wu X, Jeong EK, Chen Q, Parker DL, Lu ZR. An effective targeted nanoglobular manganese (II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. Mol Pharm 2010;7(4):936-943.
120. Xu C, Sun S. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Dalton Trans 2009 (29):5583-5591.
121. Kelly KA, Bardeesy N, Anbazhagan R, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 2008;5(4):e85.
122. Yang L, Mao H, Wang YA, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009;5(2):235-243.
123. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(5,Suppl):1S-93S.
124. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38(9):1344-1348.
125. Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 2005;9(1):22-28; discussion 28-29.
126. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40(10):923-929.
127. Wakabayashi H, Nishiyama Y, Otani T, et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008;14(1):64-69.
128. Lytras D, Connor S, Bosonnet L, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005;22(1-2):55-61; discussion 62.
129. Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005;26(10):895-901.
130. Singer E, Gschwantler M, Plattner D, et al. Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera. Eur J Gastroenterol Hepatol 2007;19(6):471-478.
131. Borbath I, Van Beers BE, Lonneux M, et al. Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatology 2005;5(6):553-561.
132. Seo S, Doi R, Machimoto T, et al. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg 2008;15(6):634-639.
133. Ruf J, Lopez Hänninen E, Oettle H, et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005;5(2-3):266-272.
134. Sperti C, Pasquali C, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 2010;14(1):131-140.
135. Sendler A, Avril N, Helmberger H, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000;24(9):1121-1129.
136. Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol 2011;78(1):142-150.
137. Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies. Surg Oncol Clin N Am 2010;19(2):235-254.
138. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28(2):117-122.
139. Zhao C, Chen Z, Ye X, et al. Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18FFDG. Nucl Med Commun 2009;30(12):971-977.
140. Flores LG, Bertolini S, Yeh HH, et al. Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. PLoS One 2009;4(11): e7977.
141. Hausner SH, Abbey CK, Bold RJ, et al. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 2009;69(14):5843-5850.
142. Kimura RH, Teed R, Hackel BJ, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 2012;18(3):839-849.
143. Amirkhanov NV, Zhang K, Aruva MR, Thakur ML, Wickstrom E. Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111) In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles. Bioconjug Chem 2010;21(4):731-740.
144. Chakrabarti A, Zhang K, Aruva MR, et al. Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3Apeptide nucleic acid-peptide nanoparticles. Cancer Biol Ther 2007;6(6):948-956.
145. Mosessian S, Duarte-Vogel SM, Stout DB, et al. INDs for PET molecular imaging probes-approach by an academic institution. Mol Imaging Biol 2014;16(4):441-448.